Publication:
Disposition kinetics of tildipirosin in alpacas after parenteral administrations

Simple item page
dc.contributor.authorGalecio, Juan Sebastian
dc.contributor.authorEscudero, Elisa
dc.contributor.authorEgas, David
dc.contributor.authorMena, Luis
dc.contributor.authorBadillo Puerta, Elena
dc.contributor.authorMarin, Pedro
dc.contributor.authorHernandis, Verónica
dc.contributor.departmentFarmacología
dc.date.accessioned2025-03-21T08:22:30Z
dc.date.available2025-03-21T08:22:30Z
dc.date.issued2023-11-10
dc.description© 2023, The Author(s). This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/. This document is the Published version of a Published Work that appeared in final form in Small Ruminant Research. To access the final edited and published work see https://doi.org/10.1016/j.smallrumres.2023.107148
dc.description.abstractTildipirosin is a macrolide antibiotic marketed in veterinary medicine to treat respiratory infections in pigs and calves. There are no pharmacokinetics studies of tildipirosin after parenteral administration in alpacas which is an extremely decisive step for determining dosage regimen. Thus, the aim of the present study was to establish the disposition fate of tildipirosin following intravenous (IV), intramuscular (IM) and subcutaneous (SC) administrations in alpacas. A crossover study was used, and each alpaca received a single dose of tildipirosin by IV and IM or SC. All the routes of administration were adequately tolerated, and no adverse reactions was observed in any alpaca. Tildipirosin in alpacas reached peak concentrations (Cmax = 0.68 µg/mL vs. 0.79 µg/mL) at 0.22 and 0.50 h (tmax) after IM and SC administration, respectively, with an absolute bioavailability of >100 % for both routes of administration. Steady-state volume of distribution and clearance were 6.02 ± 1.34 L/kg and 2.76 ± 0.28 L/h/kg, respectively. Tildipirosin presents a particular pharmacokinetic behaviour in alpacas, distinctive from other ruminant species, confirming the need to perform studies in the target species in order to promote rational dose regimens of this antimicrobial to maximize its efficacy, minimize its toxicity and avoid the emergence of resistant bacteria.es
dc.formatapplication/pdfes
dc.format.extent5es
dc.identifier.citationSmall Ruminant Research 229 (2023) 107148
dc.identifier.doihttps://doi.org/10.1016/j.smallrumres.2023.107148
dc.identifier.issnPrint: 0921-4488
dc.identifier.issnElectronic: 1879-0941
dc.identifier.urihttp://hdl.handle.net/10201/152002
dc.languageenges
dc.publisherElsevier
dc.relationSin financiación externa a la Universidades
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0921448823002444?via%3Dihub
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAlpacases
dc.subjectBioavailabilityes
dc.subjectMacrolideses
dc.subjectPharmacokineticses
dc.subjectTildipirosines
dc.titleDisposition kinetics of tildipirosin in alpacas after parenteral administrationses
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
6. Pktildipirosinalpacas.pdf
Size:
6.17 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos